Cardiovascular mortality among chronic myeloid leukemia patients in the pre-tyrosine kinase inhibitor (TKI) and TKI eras: a surveillance, epidemiology and end results (SEER) analysis

Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing

(2018) Bruno C. Medeiros et al.   BLOOD REVIEWS

An observational study on risk of secondary cancers in chronic myeloid leukemia patients in the TKI era in the United States

(2018) Vivek Kumar et al.   PeerJ

Risk of cardiac death among cancer survivors in the United States: a SEER database analysis

(2017) Omar Abdel-Rahman   Expert Review of Anticancer Therapy

Practical recommendations for reporting Fine-Gray model analyses for competing risk data

(2017) Peter C. Austin et al.   STATISTICS IN MEDICINE

Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd beyond one year.

(2017) R. A. Larson et al.   JOURNAL OF CLINICAL ONCOLOGY

Cardiovascular Events Associated With Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

(2016) Torsten Dahlén et al.   ANNALS OF INTERNAL MEDICINE

The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

(2016) Priyanka A. Pophali et al.   CANCER JOURNAL

Mortality and Vascular Events Among Elderly Patients With Chronic Myeloid Leukemia: A Retrospective Analysis of Linked SEER-Medicare Data

(2016) Kathleen Lang et al.   Clinical Lymphoma Myeloma & Leukemia

Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV

(2016) M B Miranda et al.   LEUKEMIA

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

(2016) A Hochhaus et al.   LEUKEMIA

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia

(2016) J L Steegmann et al.   LEUKEMIA

Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients

(2016) David J. Dorer et al.   LEUKEMIA RESEARCH

Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival

(2016) Jonathan Douxfils et al.   JAMA Oncology

Recent Trends in Cardiovascular Mortality in the United States and Public Health Goals

(2016) Stephen Sidney et al.   JAMA Cardiology

Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors

(2015) J S L Kloth et al.   BRITISH JOURNAL OF CANCER

Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era

(2015) Niklas Gunnarsson et al.   BRITISH JOURNAL OF HAEMATOLOGY

Use of Real-World Claim Databases to Assess Prevalence of Comorbid Conditions Relevant to the Treatment of Chronic Myelogenous Leukemia Based on National Comprehensive Network Treatment Guidelines

(2015) Elias Jabbour et al.   Clinical Lymphoma Myeloma & Leukemia

Tyrosine Kinase Inhibitor–Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia

(2015) Javid J. Moslehi et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia

(2015) M Pfirrmann et al.   LEUKEMIA

Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis

(2015) Chatree Chai-Adisaksopha et al.   LEUKEMIA & LYMPHOMA

Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials

(2015) Koji Sasaki et al.   Lancet Haematology

Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study

(2015) Preetesh Jain et al.   Lancet Haematology

Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular diseases during nilotinib treatment

(2014) Massimo Breccia et al.   ANNALS OF HEMATOLOGY

Trends in all-cause mortality among patients with chronic myeloid leukemia

(2013) Andrew M. Brunner et al.   CANCER

Tyrosine Kinase Inhibitors: Their On-Target Toxicities as Potential Indicators of Efficacy

(2013) Devron R. Shah et al.   DRUG SAFETY

Fatal progressive cerebral ischemia in CML under third-line treatment with ponatinib

(2013) K Mayer et al.   LEUKEMIA

Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis

(2013) F J Giles et al.   LEUKEMIA

Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

(2012) Jorge E. Cortes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Expanding Nilotinib Access in Clinical Trials (ENACT)

(2011) Franck E. Nicolini et al.   CANCER

Interpretability and importance of functionals in competing risks and multistate models

(2011) Per Kragh Andersen et al.   STATISTICS IN MEDICINE

Cardiovascular effects of systemic cancer treatment

(2010) Elżbieta Senkus et al.   CANCER TREATMENT REVIEWS

The duration of the use of imatinib mesylate is only weakly related to elevated BNP levels in chronic myeloid leukaemia patients

(2010) Milena S. Marcolino et al.   HEMATOLOGICAL ONCOLOGY

The use of imatinib mesylate has no adverse effects on the heart function. Results of a pilot study in patients with chronic myeloid leukemia

(2010) Milena Soriano Marcolino et al.   LEUKEMIA RESEARCH

A prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinib

(2010) Zahra Raisi Estabragh et al.   LEUKEMIA RESEARCH

Nine-year trends in achievement of risk factor goals in the US and European outpatients with cardiovascular disease

(2008) Benjamin A. Steinberg et al.   AMERICAN HEART JOURNAL

Trends in Statin Use and Low-Density Lipoprotein Cholesterol Levels Among US Adults: Impact of the 2001 National Cholesterol Education Program Guidelines

(2008) Devin Mann et al.   ANNALS OF PHARMACOTHERAPY

An evaluation of the cardiotoxicity of imatinib mesylate

(2008) Antonio Luiz Ribeiro et al.   LEUKEMIA RESEARCH

Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice

(2008) C. Louvet et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA